AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02766621 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PF-06823859
Description: Comparison of different dosages of PF-06823859 to placebo
Study NCT02766621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection SC/IV
Description: Comparison of Placebo to different doses of PF-06823859
Study NCT00103961 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: A behavioral questionnaire will occur at Week 8
Study NCT01693692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-9855 Group 1
Study NCT01693692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-9855 Group 2
Study NCT01693692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03919812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation
Description: supplementation received by subject according to their vitamin D status: insufficiency or deficiency.
Study NCT00231907 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist
Description: Live attenuated influenza vaccine (LAIV) containing approximately 10\^7 TCID50 of each of the 3 influenza strains. 0.5 mL total dose volume administered intranasally via spray applicator (approximately 0.25 mL into each nostril). Administration of Flumist in children under 5 years of age is investigational.
Study NCT00231907 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone
Description: Trivalent inactivated vaccine (TIV), licensed Fluzone preservative free pediatric dose, 0.25 mL administered intramuscularly to the anterolateral thigh muscle or deltoid muscle.
Study NCT00231907 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone
Description: Trivalent inactivated vaccine (TIV), licensed Fluzone preservative free pediatric dose, 0.25 mL administered intramuscularly to the anterolateral thigh muscle or deltoid muscle.
Study NCT01789697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cellular device/computers
Description: A random group of patients will receive text messages to their cellular device from the surgeon, as well as emails to their email addresses.
Study NCT02583438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin (Bristol-Myers Squibb Company)
Description: 6-month treatment of Saxagliptin 5mg Qd
Study NCT00116272 — intervention group
Intervention type: DRUG
Intervention: Etanercept
Description: Pregnant women previously exposed to etanercept during the first trimester. Etanercept was not administered in this non-interventional study.
Study NCT01769170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brincidofovir
Study NCT01769170 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03711630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Meditation practice will be through the InsightTimer smart device application. Participants will choose what types of meditation practices they will engage in and report their time spent meditating via REDCap.
Study NCT04961008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bottle-PEP
Description: A device that gives positive pressure from a bottle with the help of a non deflating tube
Study NCT04961008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physiotherapy
Description: Routine pulmonary physiotherapy
Study NCT03752840 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visual acuity (presenting and pinhole)
Description: Presenting and pinhole visual acuity will be assessed using the Peek Acuity mobile application. Participants meeting referral criteria will be referred to the nearest eye care center or eye hospital.
Study NCT03752840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual acuity (presenting and pinhole)
Description: Presenting and pinhole visual acuity will be assessed using the Peek Acuity mobile application. Participants meeting referral criteria will be referred to the nearest eye care center or eye hospital.
Study NCT03752840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Description: OCT will be used to image the anterior segment, the macula, and the retinal nerve fiber layer. The images will be assessed for abnormalities and participants meeting referral criteria will be referred to the local eye hospital.
Study NCT03752840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraocular pressure
Description: Intraocular pressure will be measured using an iCare tonometer. Participants meeting referral criteria will be referred to the nearest eye care center or eye hospital.
Study NCT03752840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active linkage to care
Description: Referred participants will be followed closely by study staff to ensure completion of follow-up visits.
Study NCT03752840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fundus Photography
Description: Fundus cameras will be used to image the macula and optic nerve. The images will be assessed for abnormalities and participants meeting referral criteria will be referred to the local eye hospital.
Study NCT02931201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Description: 18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post-injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
Study NCT01568346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Breast MRI
Study NCT03884114 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High-fidelity simulation
Description: The first evaluation modality studied is high fidelity (HF) simulation. In our study, this modality is considered to be the gold-standard assessment method of clinical assessment, because HF simulation corresponds to the modality which reflects the best clinical competence in hospital settings. The HF pediatric manikin used (SimBaby), is able to reproduce all the signs of an asthma exacerbation (coughing, wheezing, tachypnea, chest indrawing, seesaw respiration, cyanosis). In the simulation room, participants can use the same items that those present in the simulation game (a glass of water, paracetamol, short acting beta-agonist, controller treatment (Fluticasone), an asthma spacer with a facial mask, saline nose drops to perform nasal irrigation, oral steroids in tablets (prednisone), and a phone).
Study NCT03884114 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Simulation game
Description: EfficAsthme is a simulation game used on a tablet computer. This simulation game was developed to train parents on the management of asthma exacerbations of their children. For the purpose of the study, EfficAsthme is diverted from its original use to assess students' clinical skills. The training scenario A polluted atmosphere is used in this study. Participants need to observe the signs presented by the child, and to determine the severity of the asthma exacerbation. From a menu on the right of the screen, the participant can choose several actions, especially to provide the short acting beta-agonist.
Study NCT03884114 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Multiple choice questionnaire
Description: The third evaluation modality corresponds to a multiple choice questionnaire (MCQ) including 15 questions. As for HF-simulation and the simulation game, the MCQ starts with the same briefing and continues with 15 questions regarding the management of a moderate asthma exacerbation.
Study NCT03312920 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active anodal tDCS
Description: active anodal tDCS with memory task
Study NCT03312920 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: sham tDCS with memory task
Study NCT03312920 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active cathodal tDCS
Description: active cathodal tDCS with memory task
Study NCT01158716 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Preconditioning
Description: Patients are subjected to a 5-minute ischemia of the non-dominant arm with the use of a blood pressure cuff (inflated at 200mm Hg)
Study NCT03704649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participatory video
Description: Participatory video education is an intervention model that gives communities the film-making skills necessary to make videos that can be used in nutrition promotion. For the purposes of this study, we will be using a participatory video model as an approach to educate participants in a school-based girls club on nutrition education topics. Participants are taught how to use film equipment and accompanied to draft scripts, create characters, video-record the shots, and act (if they wish) in the video. These videos will be used in the group as a means of sharing nutrition information with students and in stimulating discussion around the nutrition topic.
Study NCT01033162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced ICCS with KPNW web resources and the Comprehensive Health Enhancement Support System (CHESS.)
Description: Half of the participating women will be randomly assigned to use an informative but static website (Basic ICCS), and half will be offered a fully interactive CHESS (Enhanced ICCS + the Basic ICCS). Study outcome data will be gathered from patients, clinicians, and the healthcare system (i.e., from the electronic medical record: EMR) for at least 8 months after study entry. We propose that the Enhanced ICCS relative to the Basic ICCS, will:~* Improve patients' sense of cancer information competence (perceived ability to obtain and use relevant information)~* Reduce patients' negative affect and increase their emotional well being~* Improve patients' sense of social support~* Improve patients' health self-efficacy~* Improve patients' ratings of experience with cancer specialty care services~* Improve patients' health related quality of life (HRQL)~* Improve clinicians' ratings of quality of patient contacts~* Reduce healthcare utilization and costs (obtained via the EMR)
Study NCT06135532 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Surgical Periodontal Treatment
Description: Nonsurgical periodontal therapy primarily aims to control microbial periodontal infection by removing bacterial biofilm, calculus, and toxins from periodontally involved root surfaces. Performing a thorough periodontal debridement under local anesthesia will stop disease progression and improve active disease's clinical signs and symptoms.
Study NCT02051803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distress Tolerance Treatment for Weight Concern (DT-W)
Study NCT02051803 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education (HE)
Study NCT01709383 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: The tDCS treatments will be applied bilaterally, with the anodal electrode placed on the left temple and the cathodal electrode placed on the right temple. The tDCS will be applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period.
Study NCT01709383 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: The sham tDCS will be applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period.
Study NCT04343716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Description: A diet low in daily carbohydrates (\<40 grams/day) provided as prepared meals.
Study NCT01288339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab + FOLFOX (DP)
Description: Panitumumab and FOLFOX will be administered to patients with DP once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
Study NCT01288339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab + FOLFOX (no-DP)
Description: Panitumumab and FOLFOX will be administered to patients with no-DP (MMP7+/p-IGF-IR-, MMP7-/p-IGF-IR+ or MMP7-/p-IGF-IR) once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
Study NCT03716557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation 4000Hz
Description: Differential programming of the Boston Scientific Precision™ Plus Spinal Cord Stimulator System
Study NCT03716557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation 10000Hz
Description: Differential programming of the Boston Scientific Precision™ Plus Spinal Cord Stimulator System
Study NCT03716557 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Stimulation 40Hz
Description: Differential programming of the Boston Scientific Precision™ Plus Spinal Cord Stimulator System
Study NCT03619083 — intervention group
Intervention type: OTHER
Intervention: SAE battery
Description: The SAE battery yields 12 variables.
Study NCT03619083 — intervention group
Intervention type: BEHAVIORAL
Intervention: Assessments
Description: Assessments of their neurocognitive performance will be assessed longitudinally, at 4 time points: prior to adjuvant treatment (post-surgery); 1 month (with a +4 week window) post-chemotherapy; and again at the 12 and 24 months (with a +4 week window) post-treatment time points. These assessment time points are denoted as T1 though T4, respectively. The assessment schedule for the HC and CT- groups will be yoked against that of the CT+ cohort.
Study NCT00768508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy
Description: Ondansetron 4 ug/kg b.i.d.for 12 weeks
Study NCT00768508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/day + Cognitive Behavioral Therapy
Description: Naltrexone 50 mg/day for 12 weeks
Study NCT00768508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral Therapy
Description: Combination of ondansetron 4 ug/kg b.i.d. and naltrexone 50 mg/day for 12 weeks
Study NCT00768508 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Cognitive Behavioral Therapy
Description: Placebo comparator
Study NCT02024672 — intervention group
Intervention type: OTHER
Intervention: Immediate postpartum placement of IUD
Description: pelvic exam, transvaginal ultrasound (3 during the course of the study), bleeding and symptom diary
Study NCT03183388 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BE-SMART
Description: Participants will take part in 12 therapy sessions, at a rate of about 1 session every one to two weeks. Sessions are anticipated to last about 1 hour each. Sessions may be focused on teaching skills to regulate emotions or regularize sleep and activity. These therapy sessions may be videotaped and audiotaped (only with the expressed written consent of the participant, and when appropriate, the participant's parent or guardian). Participants will be asked to complete worksheets and practice the skills learned from these sessions and will be asked questions about feelings. There will be an interview, assessments and scanning performed prior to treatment and at the midpoint and end to assess progress. The intervening 9 sessions may be by video telecommunication. Participants may be given devices to track actigraphy and ecological momentary assessments.
Study NCT03947827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: Participants will be randomized to receive either Minocycline or placebo added to standard oral antidepressants.
Study NCT03947827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Minocycline
Description: Participants will be randomized to receive either Minocycline or placebo added to standard oral antidepressants.
Study NCT01960595 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IV fentanyl PCA
Study NCT01960595 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local bupivacaine infiltration and post-OP IV fentanyl PCA
Study NCT01960595 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Blocks and post-OP IV fentanyl PCA
Study NCT00819364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BCRI intervention program
Description: Phase 1: The parents will receive a two-day lecture about autism to get the basic knowledge about autism intervention.~Phase 2: BCRI model intervention.Parents and children will take part in a 24-halfday workshop to learn practical teaching skills in BCRI model. Then Home-based intervention using BCRI model for 11 months. At least 28 hours of BCRI intervention per week is acquired. Doctors or therapists will meet the parents and children once per month, each for 30 minutes, totally 10 times, to monitor and give advice on the interventions.
Study NCT00819364 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard community care
Description: Phase 1: the parents will receive a two-day lecture about autism to get the basic knowledge about autism intervention.~Phase 2:Any treatment and interventions available chosen by families for children with autism and ASD, for at least one and a half years.~Phase 3:One and a half years after enrollment, parents and children will be free to take part in the BCRI model intervention which is the same as Phase 2 for experimental group lasting for one year.
Study NCT03021135 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Endoscopic Mucosal Resection
Description: Conventional Endoscopic Mucosal Resection
Study NCT03021135 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Underwater Endoscopic Mucosal Resection
Description: Underwater Endoscopic Mucosal Resection
Study NCT01787097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort® total dose 400ug/12ug
Description: Symbicort® is combination of formoterol 400ug and budesonide 12ug. Single dose
Study NCT01787097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort® total dose 800ug/24ug
Description: Symbicort® is combination of formoterol 800ug and budesonide 24ug. Single dose
Study NCT01787097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol 24ug
Description: Turbuhaler
Study NCT01787097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BUD total dose 800ug
Description: Turbuhaler
Study NCT02681575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cog-Fun - A
Description: Meta-cognitive functional intervention for improved self management in adults with ADHD
Study NCT05286944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile phone alarm reminder
Description: Patients are reminded to take their INCS using a mobile phone alarm set to ring daily
Study NCT04500496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INH
Description: 3 tablet of INH inserted by the patient 12 hours before the scheduled office hysteroscopy
Study NCT04500496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dinoprostone
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
Study NCT03556228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)
Description: Taken orally once daily
Study NCT00917033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope
Description: Orotracheal intubation
Study NCT00917033 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh direct laryngoscope
Description: Orotracheal intubation
Study NCT03306576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELS Extra composite
Description: One of the teeth will be restored using ELS composite. Procedures will be done under local anesthesia if necessary. The preparation and restoration of the tooth will be done according to to the guidelines for ordinary restorative techniques.
Study NCT03306576 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ELS composite
Description: the other teeth will be restored with a ELS resin composite with ordinary restorative techniques.
Study NCT02587702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: β-Palmitate Content
Study NCT02587702 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02587702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: β-Palmitate Content Naturely in Human Milk
Study NCT02270879 — intervention group
Intervention type: PROCEDURE
Intervention: Phacoemulsification cataract surgery
Description: Phacoemulsification of cataract (opacified lens) using clear corneal approach. Implantation of a intra-ocular lens in the capsular bag
Study NCT03402893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONEXTON Topical Gel
Description: Onexton gel applied once daily to face